If you currently hold an Abraxis/Abraxane CVR, you can continue to hold or sell that CVR following the close of the transaction, just as you did before.
In connection with the closing of the transaction, Bristol-Myers Squibb and Celgene transferred the listing of Celgene’s contingent value rights (NASDAQ: CELGZ), from NASDAQ Global Market (“NASDAQ”) to the NYSE.
The new ticker symbol is “CELG RT”.